Nikesh Engineer Email & Phone Number

Specialism/Strengths: - Unassisted detailed commercial strategy in off-patent pharmaceuticals from origination to execution of plan. - Ground up experience in developing lean & efficient Sales, Operations, Regulatory, and Technical Departments in European pharmaceutical sector.- Efficiency & Cost Containment.Head of Family Office Investments (2020-present); specialising in Healthcare, Defence, Land. $billion+ AUM.Partner OAP/LP for Gyrus Capital (2023-present).Philanthropic activities via New Rain Foundation are focussed on providing equity in education for those less privileged in remoter parts of East Africa via schools and learning centre boot camps.Founding Partner for Human Practice Foundation focussed on building and renovating government schools in Kenya and Nepal, with 100+ schools completed to date. Previously CEO & sole Director of Essential Pharma and Chemidex Pharma (2010 - 2019); - quadrupled net profits over the period concluding on $67million EBITDA on zero debt; - through targeted acquisitions, product developments, and global expansion - resulting in 181 medicinal products marketed across 27 countries- zero major or critical findings on all government compliance inspections across all countries (one of the highest rated companies for drug safety government audit findings for the period).Personal deal history in the pharma sector (excluding those under confidentiality):[Role: product analysis & strategy lead / deal origination / lead negotiator of principal terms]- Global Acquisition from Novartis Pharma (2020-21)- Divestment of UK portfolio products to Rosemont (2020)- Divestment of Essential Pharma Group to Gyrus Capital (2019)- Global Acquisition from Sanofi (2018)- Global Acquisition from Pfizer (2017)- European Acquisition from Novartis Pharma (2016)- European Acquisitions from Norgine Pharma (2015)- European Acquisitions from Norgine Pharma (2014)- European Acquisition from LEO Pharma (2013)- UK & ROI Acquisition from Astellas Pharma (2012)- Multi-product development of generic+ portfolio for European roll-out with Famar & Dechra Pharmaceuticals (2010-2011)Previous experience:- Chief Medical Advisor- Head of Pharmacovigilance & Drug Safety- UK Department of Health registered Responsible Person for GDP/WDA/MedDev/Controlled Drugs- Head of Sales & Operations- Head of Business Development- Junior Doctor for Epsom & St Helier Trust, with rotational experience in Psychiatry, Urology, Cardiology- Bachelor of Medicine, Bachelor of Surgery, Royal Free University Medical School (UCL).